Year: 2026

Introduction Exporting medicines to Nigeria changed significantly in 2026, and any exporter working from older information is operating on an outdated picture. This guide covers what’s actually current — including a major policy shift that directly affects finished pharmaceutical exports from India — alongside the customs classification, duty calculation, and clearance process that still apply to what remains importable. What WHO-GMP Certification Actually Confirms Effective April 1, 2026, Nigeria’s Federal Ministry of Finance introduced a revised Import Prohibition List banning the importation of medicaments — pharmaceutical products — from countries outside the Economic Community of West African States (ECOWAS), as part of the 2026 Fiscal Policy Measures. Since India is not an ECOWAS member, this ban applies directly to finished-dosage exports from Indian manufacturers. The banned category covers medicaments under HS Codes 3003.10.00.00 through 3004.90.90.00, including common products such as paracetamol tablets and syrups, metronidazole, cotrimoxazole, and chloroquine. Other widely used products — multivitamin capsules, aspirin, folic acid, and ointments such as penicillin and gentamicin — are now restricted to local manufacturers, while importation of pharmaceutical waste under HS Code 3006.92.00.00 remains separately and strictly forbidden. Why this matters right now: Nigeria has historically sourced 60–65% of its medicines from abroad, especially Active Pharmaceutical Ingredients, and the policy shift is designed to cut that import dependence, conserve foreign exchange, and push local manufacturing to the forefront. Industry groups including the Pharmaceutical Society of Nigeria have raised concerns that domestic manufacturing capacity isn’t yet positioned to absorb this shift. Local manufacturers cite steep operating challenges — energy costs alone account for roughly 40% of overall manufacturing cost, with many plants running on diesel or petrol generators due to unreliable grid supply. What This Means for Indian Exporters Finished Dosage Forms Are Largely Restricted Common generic finished products — many of the categories exporters have traditionally shipped to Nigeria — now fall under the ban when sourced from non-ECOWAS countries. This affects standard tablet, syrup, and capsule exports covered by the listed HS codes. APIs Remain Importable, Under Permit NAFDAC’s own March 2026 guidelines for the importation of Active Pharmaceutical Ingredients confirm that API imports continue, requiring an import permit application detailing the applicant’s address, the API source location, the specific APIs involved, and the purpose — whether importation, distribution, sale, or manufacturing of a finished pharmaceutical product. This tracks with the underlying reality that Nigerian pharmaceutical manufacturers still heavily depend on imported APIs, since the country lacks a functional petrochemical industry capable of producing them locally. This is a significant opening for Indian exporters: rather than exporting finished paracetamol or metronicazole tablets, supplying the APIs that Nigerian manufacturers need to produce them domestically remains a viable, permitted route. Specialized and Non-Locally-Produced Medicines May Still Have a Path The ban’s stated intent is to protect domestic manufacturing of commonly produced medicines. Products Nigeria doesn’t manufacture domestically — including many oncology, specialized antiretroviral, and other niche formulations — warrant individual verification against the current prohibition list and NAFDAC guidance, since blanket assumptions in either direction are risky. ECOWAS-Sourced Goods Are Exempt The restriction applies specifically to goods originating from non-ECOWAS member states, effectively encouraging regional trade within West Africa. This doesn’t open a direct path for Indian exporters, but it’s relevant context for understanding the policy’s regional trade logic. Standard Customs Process (For What Remains Importable) HS Code Classification The ban’s stated intent is to protect domestic manufacturing of commonly produced medicines. Products Nigeria doesn’t manufacture domestically — including many oncology, specialized antiretroviral, and other niche formulations — warrant individual verification against the current prohibition list and NAFDAC guidance, since blanket assumptions in either direction are risky. Duty Calculation Import duty in Nigeria is calculated using the CIF method — Cost, Insurance, and Freight — with the applicable duty rate from the HS code multiplied by the CIF value. Additional charges include a 7% surcharge on duty, 4% FCS on FOB value, 0.5% ETLS on FOB value, and 7.5% VAT on the cumulative total. Required Documentation All imports require Form M, a Pre-Arrival Assessment Report (PAAR), commercial invoice, bill of lading or airway bill, packing list, a Combined Certificate of Value and Origin (CCVO), and proof of duty payment through the NICIS II system. Regulated goods additionally require NAFDAC permits and, where applicable, a SONCAP certificate — all lodged electronically through NICIS II. Clearance Steps Customs officers verify goods against declared documentation, examine cargo physically or via scanning, and confirm HS code classification and assessed value. Duty is then assessed based on CIF value and paid in naira through an approved bank before cargo release. Regulated goods require sign-off from the relevant agency — NAFDAC clears food and pharmaceuticals specifically — after which the NCS issues a release order for final delivery. Practical Steps for Exporters Right Now ✔ Verify your specific product’s HS code against the current prohibition list before committing to any shipment — don’t rely on pre-2026 assumptions about what’s importable ✔ Consider repositioning toward API supply for Nigerian manufacturers who still need imported raw materials to produce banned finished-product categories domestically ✔ Use the Advance Ruling mechanism for any product where classification is unclear, rather than shipping and risking rejection at port ✔ Check whether your specific product is domestically manufactured in Nigeria — specialized products without local production capacity may sit outside the ban’s practical intent, but this needs individual verification, not assumption ✔ Watch for further policy updates, since this is a recently implemented and actively debated policy shift with ongoing industry pushback Conclusion Exporting medicines to Nigeria in 2026 looks meaningfully different than it did even a year ago. The finished-dosage import ban from non-ECOWAS countries is a real constraint on the traditional generics export model, but it also opens a clearer opportunity around API supply and specialized products outside Nigeria’s current manufacturing capacity. Exporters who verify their specific product’s status rather than working off outdated assumptions — and who adapt their product mix accordingly — are better positioned than those still planning around the

Introduction Ask any pharmaceutical exporter what the single most repeated requirement is across NAFDAC, PPB Kenya, and FDA Ghana applications, and the answer is the same: WHO-GMP certification. It’s the one credential that shows up in every registration dossier, every buyer due-diligence checklist, and increasingly, every tender document across African markets. Understanding WHO-GMP certification requirements for African market entry isn’t just a compliance checkbox — it’s often the difference between a manufacturer that gets shortlisted by distributors and one that doesn’t get a second look. What WHO-GMP Certification Actually Confirms WHO Good Manufacturing Practice regulations contain requirements for the methods, facilities, and controls used in the manufacture, processing, packaging, or holding of a pharmaceutical product, meant to ensure products meet the safety, quality, and efficacy they claim to represent. It’s a facility-level and systems-level certification — covering how a product is made, not just what the finished product tests as. Because Africa lacks a single continental regulator, each country manages its own approval process through its own National Medicines Regulatory Authority, with distinct requirements, formats, and timelines — though the African Medicines Agency and regional harmonization initiatives are beginning to unify these approaches. Despite this fragmentation, every major African market accepts the CTD dossier format for registration, and WHO-GMP compliance is a consistent underlying expectation across them. How WHO-GMP Is Verified Across Key African Markets Nigeria (NAFDAC) NAFDAC’s own GMP guidelines are explicitly structured around WHO good manufacturing practice principles for pharmaceutical products, and facility compliance with these standards underpins product registration eligibility. Ghana (FDA Ghana) FDA Ghana’s guideline on GMP requirements draws directly on WHO Technical Report Series guidance on good manufacturing practices for pharmaceutical products, forming the legal and technical basis for its facility inspection process. typical plant GMP audit for first-time registration reviews the pharmaceutical quality system, GMP compliance, sanitation and hygiene, qualification and validation, complaints handling, product recall procedures, and documentation practices — with the process taking approximately three months for a first-time audit and two months for renewal. Kenya and Broader Regional Standards Regulators increasingly calibrate GMP expectations against WHO-GMP and PIC/S-aligned practices, with reliance mechanisms allowing authorities to leverage prior trusted regulatory decisions, inspection reports, or WHO Prequalification outcomes to streamline national decisions — though this reliance remains at the discretion of each national authority. What a WHO-GMP Facility Audit Typically Covers Auditors generally expect documentation covering seventeen core areas at the manufacturing site, including: Pharmaceutical Quality System Good Manufacturing Practices for Pharmaceutical Products Sanitation and Hygiene Qualification and Validation Complaints Handling Product Recall Procedures Contract Production, Analysis, and Other Outsourced Activities Self-Inspection, Quality Audits, and Supplier Approval Personnel, Training, and Personal Hygiene Premises and Equipment Materials Handling Documentation Practices Good Practices in Production Good Practices in Quality Control Deficiencies identified during inspection are classified as critical, major, or other, and are communicated to the manufacturer along with a requirement for corrective and preventive action. Why WHO-GMP Matters Beyond Just Passing Registration ✔ It’s a prerequisite embedded in every downstream approval COPP issuance, FSC applications, and product registration dossiers across Nigerian, Kenyan, and Ghanaian regulators all reference GMP compliance as foundational. ✔ Buyers use it as a shortlisting filter Distributors and institutional buyers routinely screen out manufacturers who can’t produce current WHO-GMP documentation before even reviewing pricing. ✔ It supports faster registration through reliance mechanisms As African regulators increasingly reference WHO Prequalification and prior trusted regulatory decisions, a strong existing GMP compliance record can streamline registration timelines rather than starting from zero each time. ✔ It signals credibility beyond the specific product A facility-wide certification, rather than a single-product approval, tells buyers something about consistency across an entire manufacturing operation — not just one SKU. Common Gaps That Delay or Fail GMP-Linked Approvals Expired or Missing Registration Certificates Frequent issues include expired or missing registration certificates, nonconforming labels, incomplete batch documentation, and inadequate temperature-control records. Documentation Not Aligned with the Approved Dossier Regulators expect submitted documents to align precisely with the approved dossier, alongside maintained, validated shipping evidence. Incomplete Quality System Documentation Gaps in the seventeen core documentation areas — particularly self-inspection records and supplier approval processes — are common findings during facility audits. Tips for Exporters Building Toward African Market Entry ✔ Treat WHO-GMP certification as a standing operational requirement, not a one-time project completed before your first export ✔ Keep documentation across all seventeen core audit areas current and audit-ready at all times, not assembled reactively before an inspection ✔ Maintain validated temperature-control and shipping records continuously, since these are frequently flagged gaps during review ✔ Where possible, pursue WHO Prequalification alongside national GMP compliance, since it increasingly supports faster registration through regulatory reliance mechanisms Conclusion WHO-GMP certification isn’t a single hurdle to clear before entering African markets — it’s the foundation that NAFDAC, PPB, and FDA Ghana registration processes are all built on top of, and increasingly, what buyers themselves screen for before any commercial conversation even starts. Manufacturers who treat GMP compliance as an ongoing operational standard, rather than a certificate to renew reactively, move through registration faster and win more buyer trust across every African market they enter. Salvavidas Pharma, a WHO-GMP certified pharmaceutical manufacturer based in Surat, India, maintains this standard across its API, generics, oncology, and anti-HIV product lines specifically to support smooth, compliant entry into markets like Nigeria, Kenya, and Ghana.

Introduction Before a single carton of medicine ships to Lagos, Nairobi, or Accra, an Indian exporter needs a specific stack of licenses in place at home — separate from whatever registration the destination country requires. Getting a pharma export license India to Africa deals with isn’t one document, but a layered set of approvals from DGFT, the state drug authority, and CDSCO, each serving a different regulatory purpose. This guide walks through exactly what’s needed on the Indian side, step by step, before a product is even ready to begin NAFDAC, PPB, or FDA Ghana registration on the African side. Why This Is a Layered Process, Not One License Unlike many product categories, pharmaceuticals require export approval at two separate levels in India: a general trade-level authorization that applies to any exported goods, and a pharma-specific regulatory layer governed by the Drugs and Cosmetics Act. Key reasons the process has multiple layers: An IEC (Importer Exporter Code) is a general business requirement for any Indian company engaged in import or export, and is not specific to pharmaceuticals. A drug export licence, issued under the Drugs and Cosmetics Act by CDSCO or the State Drug Controller, is specific to pharmaceutical products and required in addition to the IEC. Certain products or destination countries may trigger additional CDSCO-specific approval requirements beyond the base export license Each license serves customs, quality-control, and international-compliance purposes independently Licenses and Registrations Required 1. Import Export Code (IEC) Issued by the Directorate General of Foreign Trade (DGFT), this is mandatory for all exports regardless of product category — the foundational registration needed before any export business can legally operate. 2. Drug Manufacturing / Wholesale License Issued under the Drugs and Cosmetics Act, 1940, this confirms the exporting entity is authorized to manufacture or deal in pharmaceutical products domestically — a prerequisite for pharma-specific export activity. 3. Drug Export NOC (No Objection Certificate) Granted by CDSCO or the State Licensing Authority, this NOC allows Indian manufacturers to legally export pharmaceutical products abroad, covering approved, unapproved, and banned drug categories depending on the case. Manufacturers must hold a valid license under Form 25 or 28 and comply with quality control standards to apply, with the application requiring an export order, covering letter, purchase order, manufacturing license, and invoice. 4. Certificate of Pharmaceutical Product (COPP) Exporters must obtain a COPP issued by CDSCO for each pharmaceutical product intended for export, certifying that the product is manufactured in compliance with Indian regulatory standards.</cite> This is the document African regulators (NAFDAC, PPB, FDA Ghana) will require as part of their own product registration process. 5. Free Sale Certificate (FSC) Exporters may also be required to provide an FSC issued by CDSCO, attesting to the product’s free-sale status in India. 6. GMP Certification This ensures manufacturing follows WHO Good Manufacturing Practices — increasingly a baseline expectation from African buyers and regulators alike, not just a nice-to-have. 7. GST Registration Required for export compliance, with exports treated as zero-rated under GST. Step-by-Step Process Step 1: Register for an IEC Apply through DGFT — this is the starting point for any export activity and typically the fastest of the required registrations. Step 2: Confirm Your Manufacturing/Wholesale Drug License Is Current This should already be in place for any operating pharmaceutical manufacturer, but confirm it covers the specific product categories you intend to export. Step 3: Apply for the Drug Export NOC Submit the export order, manufacturing license, invoice, and supporting documents to CDSCO or your State Licensing Authority. Step 4: Obtain COPP and FSC for Each Product These are issued per product, not per company — budget time for this on a product-by-product basis as you expand your export catalog. Step 5: Confirm GMP Certification Status Ensure your manufacturing site’s WHO-GMP certification is current, since this underpins COPP issuance and is frequently required directly by African regulators too. Step 6: Proceed to Destination-Country Registration With IEC, drug license, NOC, COPP, and FSC in place, you’re positioned to begin the separate registration process with NAFDAC, PPB, or FDA Ghana for your target African market. Common Mistakes That Delay the Process Treating the IEC as Sufficient on Its Own The IEC gets you export-eligible as a business, but pharmaceutical products still need the drug-specific NOC, COPP, and FSC layered on top. Applying for COPP/FSC Too Late Since African regulators require these as part of their own registration dossiers, delays here cascade directly into delays on the NAFDAC, PPB, or FDA Ghana side. Inconsistent Documentation Across Licenses Product names, manufacturing site details, and specifications should match exactly across the IEC, drug license, NOC, and COPP to avoid queries at any stage. Assuming One-Time Approval Covers All Products COPP and FSC are typically product-specific and time-bound, requiring renewal and reapplication as your export portfolio grows. Tips for a Smoother Process ✔ Sequence your applications — IEC first, then drug-specific approvals — rather than trying to parallel-process everything at once ✔ Apply for COPP and FSC for new products well ahead of any African market registration timeline, since those documents feed directly into NAFDAC/PPB/FDA Ghana applications ✔ Keep WHO-GMP certification current across your facility, since it underlies most of the downstream approvals ✔ Maintain a master compliance file per product covering every Indian-side document, to keep information consistent when it’s reused in destination-country dossiers Conclusion A pharma export license India to Africa route requires isn’t a single certificate — it’s a sequence of India-side approvals (IEC, drug license, export NOC, COPP, FSC) that together make a product export-ready, before destination-country registration with NAFDAC, PPB, or FDA Ghana even begins. Exporters who treat this as a structured sequence, rather than a single application, move products to market faster and with far fewer compliance surprises. Partnering with an experienced Pharma export company in India that has these approvals in place across a broad product portfolio removes much of this groundwork for African buyers and distributors.